Company Description
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health.
The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response.
It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022.
Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | James Rolke |
Contact Details
Address: 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 United States | |
| Phone | 650 800 3717 |
| Website | revbiosciences.com |
Stock Details
| Ticker Symbol | REVB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1810560 |
| CUSIP Number | 76135L804 |
| ISIN Number | US76135L8046 |
| Employer ID | 84-3898466 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James M. Rolke | Chairman and Chief Executive Officer |
| Chester Stanley Zygmont III | Chief Financial Officer and Corporate Secretary |
| Sandra Vedrick | Vice President of Human Resources and Investor Relations |
| Carol Odle | Senior Director of Clinical Projects |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | DEF 14A | Other definitive proxy statements |
| Feb 11, 2026 | EFFECT | Notice of Effectiveness |
| Feb 11, 2026 | 424B3 | Prospectus |
| Feb 6, 2026 | PRE 14A | Other preliminary proxy statements |
| Jan 30, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 29, 2026 | 8-K | Current Report |